A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7807-7816

  Ebbinghaus, Scot ^a   Rubin, Eric ^b   Hersh, Evan ^a   Cranmer, Lee D ^a   Bonate, Peter L ^c   Fram, Robert J ^c   Jekunen, Antti ^c   Weitman, Steve ^c   Hammond, Lisa A ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOLASTATIN 15; ILX 651; TASIDOTIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG MECHANISM; DYSPEPSIA; FATIGUE; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; HYPESTHESIA; HYPONATREMIA; ILEUS; LETHARGY; LIVER DYSFUNCTION; LIVER METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; SORE THROAT; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; OLIGOPEPTIDES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 27744536541     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0909     Document Type: Article

References (28)

1. Pettit GR, Kamano Y, Herald CL, et al. The isolation and structure of a remarkable marine animal constituent: dolastatin 10. J Am Chem Soc 1987;109:6883-5.
2. Kamano Y, Herald CL, Pettit GR, inventor(s). Cell growth inhibitory substance. United States patent US 4816444. 1989 March 28.
3. Pettit GR, Kamano Y, Dufresne C, Cerny RL, Herald CL, Schmidt JM. Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. J Org Chem 1989;54:6005-6.
4. Pettit GR, Kamano Y, inventor(s). Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15. United States patent US 4879278. 1989 November 7.
5. Beckwith M, Urba W, Longo D. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst 1993;85:483-8.
6. Smith P, Nelson C, Janssen B, et al. Preclinical antitumor activity of a novel water-soluble dolastatin 15 analogue (LU103793). Proc Am Assoc Cancer Res 1995;36:393.
7. Kalemkerian GP, Ou X, Adil MR, et al. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 1999;43:507-15.
8. Turner T, Jackson WH, Pettit GR, Wells A, Kraft AS. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Prostate 1998;34:175-81.
9. Jordan MA, Walker D, de Arruda M, Barlozzari T, Panda D. Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanisms for its antitumor action. Biochemistry 1998;37:17571-8.
10. Mross K, Berdel WE, Fiebig HH, Velagapudi R, von Broen IM, Unger C. Clinical and pharmacologic phase I study of Cemadotin-HCI (LU103793), a novel antimitotic peptide, given as 24 hour infusion in patients with advanced cancer: a study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society. Ann Oncol 1998;9:1323-30.
11. Mross K, Herbst K, Berdel WE, et al. Phase I clinical and pharmacokinetic study of LU103793 (cemadotin hydrochloride) as an intravenous bolus injection in patients with metastatic solid tumors. Onkologie 1996;19:490-5.
12. Wolff I, Bruntsch U, Cavalli F, et al. Phase I clinical and pharmacokinetic study of the dolastatin analogue LU103793 on a weekly × 4 schedule. Ann Oncol 1996;7:124.
13. Villalona-Calero M, Baker SD, Hammond L, et al. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. J Clin Oncol 1998;16:2770-9.
14. de Arruda M, Cocchiaro CA, Nelson CM, et al. LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res 1995;55:3085-92.
15. Stephenson K, Prasad V, Weitman S, Luduena RF. ILX651 disrupts microtubule assembly by two mechanisms. Proc Am Assoc Cancer Res 2004;45:1297 (A5616).
16. Roth S, Krumbholz R, Arthaud L, et al. In vivo and in vitro antitumor effects of ILX651, a pentapeptide with a novel mechanism of action. Proc Am Assoc Cancer Res 2004;45:488 (A2121).
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
18. Lewiston DE, Walker A, Bonate PL, et al. Determination of ILX651 (a synthetic analog of dolastatin-15) in human plasma by an LC/MS/MS method. American Association of Pharmaceutical Scientists; 2004 (M1012).
19. Cawello W, editor. Parameters for compartment-free pharmacokinetics: standardization of study design, data analysis, and reporting. Aachen (Germany): Shaker Verlag; 1999.
20. Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: a report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Inf J 1995;29:1039-48.
21. Boxenbaum M, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol 1995;35:763-6.
22. Schoffski P, Thate B, Beutel G, et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour Intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 2004;15:671-9.
23. Otani M, Natsume T, Watanabe JI, et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000;91:837-44.
24. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002;29:21-33.
25. Hammond LA, Ruvuna F, Cunningham CC, et al: Phase I (Ph) I evaluation of the dolastatin analogue synthadotin (Syn-D; ILX651): pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2004;23:212s (A3068).
26. Bonate P, Ebbinghaus S, Eder JP, et al. Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors. Proc Am Soc Clin Oncol 2004;23:147s (A2082).
27. Mita A, Hammond LA, Garrison M, et al. A phase I and pharmacokinetic study of ILX651 administered intravenously weekly for 3 weeks every 4 weeks in patients with advanced solid tumors. Clin Cancer Res 2003;9:16s (A264).
28. Weiss GR, Mita A, Garrison M, et al. Phase I, pharmacokinetic (PK) study of synthadotin (SYN-D; ILX651), a next generation antitubulin, administered IV weekly × 3 weeks every 4 weeks (WX3Q4W). Proc Am Soc Clin Oncol 2004;22:213s (3073).